Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

BACKGROUND: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. METHODS AND...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Brookes, R, Hill, A, Owiafe, P, Ibanga, H, Jeffries, D, Donkor, SA, Fletcher, H, Hammond, A, Lienhardt, C, Adegbola, R, McShane, H
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Public Library of Science 2008

Παρόμοια τεκμήρια

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
ανά: Roger H Brookes, κ.ά.
Έκδοση: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
ανά: Roger H. Brookes, κ.ά.
Έκδοση: (2011-01-01)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
ανά: Ibanga, H, κ.ά.
Έκδοση: (2006)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
ανά: Owiafe, P, κ.ά.
Έκδοση: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
ανά: Ota, M, κ.ά.
Έκδοση: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
ανά: Ota, M, κ.ά.
Έκδοση: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
ανά: Pathan, A, κ.ά.
Έκδοση: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
ανά: Pathan, A, κ.ά.
Έκδοση: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
ανά: Meyer, J, κ.ά.
Έκδοση: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
ανά: Mcshane, H, κ.ά.
Έκδοση: (2005)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
ανά: Whelan, K, κ.ά.
Έκδοση: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
ανά: Meyer, J, κ.ά.
Έκδοση: (2013)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
ανά: Rowland, R, κ.ά.
Έκδοση: (2012)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
ανά: Ota, M, κ.ά.
Έκδοση: (2007)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
ανά: Harris, S, κ.ά.
Έκδοση: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Έκδοση: (2011-01-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
ανά: White, A, κ.ά.
Έκδοση: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
ανά: Minassian, A, κ.ά.
Έκδοση: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
ανά: Hawkridge, T, κ.ά.
Έκδοση: (2008)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
ανά: Betts, G, κ.ά.
Έκδοση: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
ανά: Kathryn T. Whelan, κ.ά.
Έκδοση: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
ανά: Sander, C, κ.ά.
Έκδοση: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
ανά: Rowland, R, κ.ά.
Έκδοση: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
ανά: Tameris, M, κ.ά.
Έκδοση: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
ανά: Thomas, Z, κ.ά.
Έκδοση: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
ανά: Minhinnick, A, κ.ά.
Έκδοση: (2016)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
ανά: Odutola, A, κ.ά.
Έκδοση: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
ανά: Odutola, A, κ.ά.
Έκδοση: (2012)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
ανά: Fletcher, H, κ.ά.
Έκδοση: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
ανά: Wajja, A, κ.ά.
Έκδοση: (2017)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
ανά: Griffiths, K, κ.ά.
Έκδοση: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
ανά: Griffiths, K, κ.ά.
Έκδοση: (2011)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
ανά: Gareth Betts, κ.ά.
Έκδοση: (2012-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
ανά: Harris, S, κ.ά.
Έκδοση: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
ανά: Riste, M, κ.ά.
Έκδοση: (2021)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
ανά: Tameris, M, κ.ά.
Έκδοση: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
ανά: Satti, I, κ.ά.
Έκδοση: (2014)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
ανά: Wilkie, M, κ.ά.
Έκδοση: (2019)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
ανά: Dieye, T, κ.ά.
Έκδοση: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
ανά: Mcshane, H
Έκδοση: (2008)